1
|
Kugener VF, Freedland ES, Maynard KI, Aimer O, Webster PS, Salas M, Gossell-Williams M. Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. Drug Saf 2021; 44:843-852. [PMID: 33993430 PMCID: PMC8123099 DOI: 10.1007/s40264-021-01078-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/29/2021] [Indexed: 12/17/2022]
Abstract
This review is intended to present perspectives from the US experience in enhancing pharmacovigilance on current practices and future opportunities. Best practices concepts could be applied worldwide through the presentation of how three pillars of pharmacovigilance: (1) medical and scientific excellence, (2) operational and compliance excellence, and (3) knowledge sharing and experts development in the field could serve as a framework for the establishment of an efficient and successful global pharmacovigilance system.
Collapse
Affiliation(s)
- Veronique F. Kugener
- Global Patient Safety Evaluation, Research & Development, Takeda Pharmaceuticals International Co., 300 Massachusetts Avenue, Cambridge, MA 02139 USA
| | - Eric S. Freedland
- Global Patient Safety Evaluation, Research & Development, Takeda Pharmaceuticals International Co., 300 Massachusetts Avenue, Cambridge, MA 02139 USA
| | - Kenneth I. Maynard
- Global Patient Safety Evaluation, Research & Development, Takeda Pharmaceuticals International Co., 300 Massachusetts Avenue, Cambridge, MA 02139 USA
| | | | | | - Maribel Salas
- Daiichi Sankyo, Inc. and CCEB/CPeRT, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
| | - Maxine Gossell-Williams
- Section of Pharmacology and Pharmacy, Faculty of Medical Sciences Teaching and Research Complex, University of The West Indies, Kingston, Jamaica
| |
Collapse
|
2
|
Esteban E, Bustos RH, García JC, Jáuregui E. Biosimilars: An Approach to some Current Worldwide Regulation Frameworks. ACTA ACUST UNITED AC 2019; 14:16-40. [DOI: 10.2174/1574884713666181025142928] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 10/12/2018] [Accepted: 10/19/2018] [Indexed: 12/26/2022]
Abstract
Developing new biologics has led to regulations and norms aimed at guaranteeing their
safety, quality and effectiveness, in terms of marketing, prescription, use, interchangeability and
switching. Biologics are of great importance in treating patients suffering from rheumatic, autoimmune,
inflammatory and neoplastic diseases. The expiry/lapse of reference biologics or originators’
patents has meant that developing biosimilars involves accompanying legal requirements for their
approval in countries worldwide. This paper has thus approached the situation of biosimilar regulation
worldwide, the pertinent technical concepts and regulatory differences in some countries of
interest.
Collapse
Affiliation(s)
- Efraín Esteban
- Evidence-Based Therapeutic Group, Clinical Pharmacology, Universidad de la Sabana, Chia, Colombia
| | - Rosa-Helena Bustos
- Evidence-Based Therapeutic Group, Clinical Pharmacology, Universidad de la Sabana, Chia, Colombia
| | - Julio-César García
- Evidence-Based Therapeutic Group, Clinical Pharmacology, Universidad de la Sabana, Chia, Colombia
| | | |
Collapse
|
3
|
Nabhan C, Valley A, Feinberg BA. Barriers to Oncology Biosimilars Uptake in the United States. Oncologist 2018; 23:1261-1265. [PMID: 30049886 PMCID: PMC6291332 DOI: 10.1634/theoncologist.2018-0066] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 05/17/2018] [Accepted: 05/17/2018] [Indexed: 01/13/2023] Open
Abstract
Biosimilars are biological compounds that contain an active substance that is similar to the active substance in an already approved biologic. This commentary focuses on the barriers to the use of biosimilars in the United States.
Collapse
Affiliation(s)
- Chadi Nabhan
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, Ohio, USA
| | - Amy Valley
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, Ohio, USA
| | - Bruce A Feinberg
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, Ohio, USA
| |
Collapse
|
4
|
Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 2018; 77:165-174. [PMID: 28866648 DOI: 10.1136/annrheumdis-2017-211937] [Citation(s) in RCA: 138] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 07/20/2017] [Accepted: 08/12/2017] [Indexed: 12/30/2022]
Abstract
The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, and pharmacologists, patients and a regulator from ten countries. Four key topics regarding biosimilars were identified through a process of discussion and consensus. Using a Delphi process, specific questions were then formulated to guide a systematic literature review. Relevant English-language publications through November 2016 were searched systematically for each topic using Medline; selected papers and pertinent reviews were examined for additional relevant references; and abstracts presented at the 2015 and 2016 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) annual scientific meetings were searched for those about biosimilars. The experts used evidence obtained from these studies to develop a set of overarching principles and consensus recommendations. The level of evidence and grade of recommendation were determined for each. By the search strategy, 490 references were identified. Of these, 29 full-text papers were included in the systematic review. Additionally, 20 abstracts were retrieved from the ACR and EULAR conference abstract databases. Five overarching principles and eight consensus recommendations were generated, encompassing considerations regarding clinical trials, immunogenicity, extrapolation of indications, switching between bio-originators and biosimilars and among biosimilars, and cost. The level of evidence and grade of recommendation for each varied according to available published evidence. Five overarching principles and eight consensus recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases were developed using research-based evidence and expert opinion.
Collapse
Affiliation(s)
- Jonathan Kay
- Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA
| | - Monika M Schoels
- Department of Internal Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
| | - Thomas Dörner
- Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany
| | - Paul Emery
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
| | - Tore K Kvien
- Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
| | - Josef S Smolen
- Department of Internal Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Ferdinand C Breedveld
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
5
|
|
6
|
Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr 2015; 61:503-8. [PMID: 26154031 DOI: 10.1097/mpg.0000000000000903] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Because the patents for biopharmaceutical monoclonal antibodies have or soon will expire, biosimilars are coming to the market. This will most likely lead to decreased drug costs and so easier access to these expensive agents. Extrapolation, however, of the limited available clinical data from adults with rheumatologic diseases to children with inflammatory bowel disease (IBD) should be done with caution and needs some considerations.Postmarketing surveillance programs for efficacy, safety, and immunogenicity should become mandatory in children with IBD using biosimilars, as for all biological drugs.
Collapse
|
7
|
Abad Hernández MÁ, Andreu JL, Caracuel Ruiz MÁ, Belmonte Serrano MÁ, Díaz-González F, Moreno Muelas JV. Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. ACTA ACUST UNITED AC 2015; 11:269-78. [DOI: 10.1016/j.reuma.2015.03.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Accepted: 03/06/2015] [Indexed: 02/09/2023]
|
8
|
Introduction and commentary: Biosimilars—clinical trial and safety considerations. Semin Arthritis Rheum 2015; 44:S1. [DOI: 10.1016/j.semarthrit.2014.10.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 10/24/2014] [Indexed: 11/18/2022]
|
9
|
Bocquet F, Paubel P, Fusier I, Cordonnier AL, Sinègre M, Le Pen C. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2015; 13:47-59. [PMID: 25189295 DOI: 10.1007/s40258-014-0125-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
BACKGROUND Patent expiries on leading biologics are creating new momentum in the market for biosimilars (copies of off-patent biologics), paving the way for their development. However, little is known about the factors influencing the competition between biosimilars and their reference products (REF). OBJECTIVES The aim of this study was to analyse key global erythropoietin (EPO) markets and factors affecting biosimilar EPO (BIOSIM-EPO) uptakes, and to identify countries where BIOSIM-EPOs have gained significant market shares. METHODS Inclusion criteria for countries in the study were a biosimilar regulatory framework similar to the EU framework, and biological market value higher than US$2.5 billion. Factors evaluated included EPO market size, EPO retail/hospital distribution mix, national incentives to use biosimilars and BIOSIM-EPO/REF price differences. IMS Health provided EPO consumption in volumes, values, and EPO ex-manufacturer prices from 2007 to 2012. RESULTS Japan: large-sized market, mixed retail/hospital distribution, no incentives, low BIOSIM-EPO uptake (6.8 % in 2012). France: large-sized market, dominant retail distribution, no incentives, low BIOSIM-EPO uptake (5.8 %). Spain and Italy: medium-sized market, dominant hospital distribution, no incentives, moderate BIOSIM-EPO uptakes (11.5 and 8.6 %). Germany: small-sized market, dominant retail distribution, presence of incentives, high BIOSIM-EPO uptake (30.4 %). UK: small-sized market, mixed retail/hospital distribution, no incentives, low BIOSIM-EPO uptake (2.0 %). BIOSIM-EPO/REF price differences play no role at a global level (-10.8 % in Germany and -26.9 % in Japan). CONCLUSIONS EPO markets have proven to be highly country-specific. EPO market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO/REF price differences may not be determining factors of BIOSIM-EPO uptakes. Prescription and substitution incentives to use BIOSIM-EPO appear to be determining factors in Germany. The heterogeneity of national EPO markets makes it impossible to outline country profile types with significant BIOSIM-EPO penetrations.
Collapse
Affiliation(s)
- François Bocquet
- Laboratory for the Economics and Management of Health Organizations, Dauphine University, Place du Maréchal de Lattre de Tassigny, 75775, Paris, CEDEX 16, France,
| | | | | | | | | | | |
Collapse
|
10
|
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol 2015; 34:1427-33. [DOI: 10.1007/s10067-014-2835-4] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Accepted: 11/20/2014] [Indexed: 12/30/2022]
|
11
|
Abstract
Biopharmaceuticals, produced by recombinant DNA technology, are generally more complicated to produce than small molecule drugs. As patents around the development and manufacturing of these biopharmaceuticals expire, biosimilars are being developed as comparable and more affordable alternatives to improve patient access and market competition. This commentary explains what a biosimilar is; it compares and contrasts biosimilar production with that of small molecule, generic, and other biological drugs; and it describes basic principles of the nonclinical development program for monoclonal antibody biosimilars.
Collapse
Affiliation(s)
- A M Ryan
- Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA
| |
Collapse
|
12
|
Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol 2014; 55 Suppl 3:S123-32. [PMID: 24965228 DOI: 10.1002/jcph.339] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 06/01/2014] [Indexed: 12/21/2022]
Abstract
Monoclonal antibodies have become mainstays of treatment for many diseases. After more than a decade on the Canadian market, a number of authorized monoclonal antibody products are facing patent expiry. Given their success, most notably in the areas of oncology and autoimmune disease, pharmaceutical and biotechnology companies are eager to produce their own biosimilar versions and have begun manufacturing and testing for a variety of monoclonal antibody products. In October of 2013, the first biosimilar monoclonal antibody products were approved by the European Medicines Agency (Remsima™ and Inflectra™). These products were authorized by Health Canada shortly after; however, while the EMA allowed for extrapolation to all of the indications held by the reference product, Health Canada limited extrapolation to a subset of the indications held by the reference product, Remicade®. The purpose of this review is to discuss the Canadian regulatory framework for the authorization of biosimilar mAbs with specific discussion around the clinical requirements for establishing (bio)-similarity and to present the principles that are used in the clinical assessment of New Drug Submissions for intended biosimilar monoclonal antibodies. Health Canada's current views regarding indication extrapolation, product interchangeability, and post-market surveillance are discussed as well.
Collapse
Affiliation(s)
- Bradley J Scott
- Centre for the Evaluation of Radiopharmaceuticals and Biotherapeutics, Biologics and Genetic Therapies Directorate, Health Products and Food Branch, Health Canada, Ottawa, K1A 0K9, Canada
| | | | | |
Collapse
|
13
|
Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42:177-83. [PMID: 24962198 DOI: 10.1016/j.biologicals.2014.05.005] [Citation(s) in RCA: 94] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2014] [Revised: 05/22/2014] [Accepted: 05/30/2014] [Indexed: 12/14/2022] Open
Abstract
A biosimilar is intended to be highly similar to a reference biologic such that any differences in quality attributes (i.e., molecular characteristics) do not affect safety or efficacy. Achieving this benchmark for biologics, especially large glycoproteins such as monoclonal antibodies, is challenging given their complex structure and manufacturing. Regulatory guidance on biosimilars issued by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency indicates that, in addition to a demonstration of a high degree of similarity in quality attributes, a reduced number of nonclinical and clinical comparative studies can be sufficient for approval. Following a tiered approach, clinical studies are required to address concerns about possible clinically significant differences that remain after laboratory and nonclinical evaluations. Consequently, a critical question arises: can clinical studies that satisfy concerns regarding safety and efficacy in one condition support "indication extrapolation" to other conditions? This question will be addressed by reviewing the case of a biosimilar to infliximab that was approved recently in South Korea, Europe, and Canada for multiple indications through extrapolation. The principles discussed should also apply to biosimilars of other monoclonal antibodies that are approved to treat multiple distinct conditions.
Collapse
Affiliation(s)
- Brian G Feagan
- Robarts Clinical Trials Inc., Western University, 100 Perth Drive, London, ON, N6A 5K8, Canada.
| | | | | | | | - Vincent Ho
- University of British Columbia, Vancouver, BC, Canada
| | | | - Guangyong Zou
- Robarts Clinical Trials Inc., Western University, 100 Perth Drive, London, ON, N6A 5K8, Canada
| | - Zhenhua Xu
- Janssen Research and Development, LLC, Spring House, PA, USA
| | - Gopi Shankar
- Janssen Research and Development, LLC, Spring House, PA, USA
| | | | | |
Collapse
|
14
|
Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, Feagan BG. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. CANADIAN JOURNAL OF GASTROENTEROLOGY = JOURNAL CANADIEN DE GASTROENTEROLOGIE 2013; 27:567-71. [PMID: 24106727 PMCID: PMC3805336 DOI: 10.1155/2013/327120] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Shane M Devlin
- Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta
| | - Brian Bressler
- University of British Columbia, Vancouver, British Columbia
| | - Charles N Bernstein
- IBD Clinical and Research Centre and Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba
| | - Richard N Fedorak
- Division of Gastroenterology, University of Alberta, Edmonton, Alberta
| | - Alain Bitton
- Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec
| | - Harminder Singh
- IBD Clinical and Research Centre and Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba
| | - Brian G Feagan
- Robarts Clinical Trials, Robarts Research Institute, and Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Ontario
| |
Collapse
|